Medicine and Health Sciences Commons^™

Influence Of The Human Lipidome On Epicardial Fat Volume In Mexican American Individuals, Ana C. Leandro, Laura F. Michael, Marcio Almeida, Mikko Kuokkanen, Kevin Huynh, Corey Giles, Thy Duong, Vincent P. Diego, Ravindranath Duggirala, Geoffrey D. Clarke, John Blangero, Joanne E. Curran

School of Medicine Publications and Presentations

Introduction: Cardiovascular disease (CVD) is the leading cause of mortality worldwide and is the leading cause of death in the US. Lipid dysregulation is a well-known precursor to metabolic diseases, including CVD. There is a growing body of literature that suggests MRI-derived epicardial fat volume, or epicardial adipose tissue (EAT) volume, is linked to the development of coronary artery disease. Interestingly, epicardial fat is also actively involved in lipid and energy homeostasis, with epicardial adipose tissue having a greater capacity for release and uptake of free fatty acids. However, there is a scarcity of knowledge on the influence of plasma …

Association Of Fatal And Nonfatal Cardiovascular Outcomes With 24-Hour Mean Arterial Pressure, Jesus D. Melgarejo, Wen-Yi Yang, Lutgarde Thijs, Kei Asayama, Tine W. Hansen, Fang-Fei Wei, Masahiro Kikuya, Takayoshi Ohkubo, Eamon Dolan, Gladys E. Maestre

School of Medicine Publications and Presentations

Major adverse cardiovascular events are closely associated with 24-hour blood pressure (BP). We determined outcome-driven thresholds for 24-hour mean arterial pressure (MAP), a BP index estimated by oscillometric devices. We assessed the association of major adverse cardiovascular events with 24-hour MAP, systolic BP (SBP), and diastolic BP (DBP) in a population-based cohort (n=11 596). Statistics included multivariable Cox regression and the generalized R2 statistic to test model fit. Baseline office and 24-hour MAP averaged 97.4 and 90.4 mm Hg. Over 13.6 years (median), 2034 major adverse cardiovascular events occurred. Twenty-four-hour MAP levels of <90 >(normotension, n=6183), 90 to <92 >(elevated MAP, n=909), …

Heritability Of 596 Lipid Species And Genetic Correlation With Cardiovascular Traits In The Busselton Family Heart Study, Gemma Cadby, Phillip E. Melton, Nina S. Mccarthy, Corey Giles, Natalie A. Mellett, Kevin Huynh, Joseph Hung, John Beilby, Marie-Pierre Dube, Gerald F. Watts, John Blangero, Peter J. Meikle, Eric K. Moses

School of Medicine Publications and Presentations

Introduction: Cardiovascular disease (CVD) is the leading cause of death worldwide, and genetic investigations into the human lipidome may provide insight into CVD risk. The aim of this study was to estimate the heritability of circulating lipid species and their genetic correlation with CVD traits.

Methods: Targeted lipidomic profiling was performed on 4492 participants from the Busselton Family Heart Study to quantify the major fatty acids of 596 lipid species from 33 classes. We estimated narrow-sense heritabilities of lipid species/classes, and their genetic correlations with eight CVD traits – body mass index, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, triglycerides, …

Novel Pharmacological Therapy In Type 2 Diabetes Mellitus With Established Cardiovascular Disease: Current Evidence, Leonardo Pozo, Fatimah Bello, Andres Suarez, Francisco E. Ochoa-Martinez, Yamely Mendez, Chelsea H. Chang, Salim Surani

School of Medicine Publications and Presentations

Cardiovascular diseases (CVDs) remain the leading cause of death in the world and in most developed countries. Patients with type 2 diabetes mellitus (T2DM) suffer from both microvascular and macrovascular diseases and therefore have higher rates of morbidity and mortality compared to those without T2DM. If current trends continue, the Center for Disease Control and Prevention estimates that 1 in 3 Americans will have T2DM by year 2050. As a consequence of the controversy surrounding rosiglitazone and the increasing prevalence of diabetes and CVDs, in 2008 the Food and Drug Administration (FDA) established new expectations for the evaluation of new …